vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
15.41
-0.24 (-1.53%)
Nov 21, 2024, 10:59 AM EST - Market open
vTv Therapeutics Employees
vTv Therapeutics had 16 employees as of December 31, 2023. The number of employees increased by 3 or 23.08% compared to the previous year.
Employees
16
Change (1Y)
3
Growth (1Y)
23.08%
Revenue / Employee
$62,500
Profits / Employee
-$1,144,125
Market Cap
46.39M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
LakeShore Biopharma | 758 |
BGM Group | 298 |
Rapid Micro Biosystems | 193 |
Cytosorbents | 186 |
Vor Biopharma | 168 |
Prelude Therapeutics | 128 |
Aadi Bioscience | 89 |
Lucid Diagnostics | 70 |
VTVT News
- 3 months ago - vTv Therapeutics Announces 2024 Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold - GlobeNewsWire
- 5 months ago - vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes - GlobeNewsWire
- 6 months ago - CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETING - PRNewsWire
- 6 months ago - vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 8 months ago - CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT - PRNewsWire
- 9 months ago - vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 months ago - vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes - GlobeNewsWire